COCRYSTAL PHARMA NEW O.N. (8CC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COCRYSTAL PHARMA NEW O.N. (8CC) has a cash flow conversion efficiency ratio of -0.274x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.74 Million ≈ $-2.03 Million USD) by net assets (€6.33 Million ≈ $7.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 8CC equity to assets ratio to measure how much of total assets are equity-financed.
COCRYSTAL PHARMA NEW O.N. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how COCRYSTAL PHARMA NEW O.N.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore 8CC operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
COCRYSTAL PHARMA NEW O.N. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COCRYSTAL PHARMA NEW O.N. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Geoprima Solusi Tbk PT
JK:GPSO
|
-0.036x |
|
Volt Power Group Ltd
AU:VPR
|
0.043x |
|
Mentiga Corporation Bhd
KLSE:5223
|
0.008x |
|
Oxford Nanopore Technologies Ltd
LSE:ONT
|
-0.040x |
|
Sanko Diecasting (Thailand) Public Company Limited
BK:SANKO
|
0.092x |
|
Kier Group PLC
LSE:KIE
|
0.457x |
|
Noble Helium Ltd
AU:NHE
|
-0.026x |
|
CLEANTEK Industries Inc
V:CTEK
|
0.193x |
Annual Cash Flow Conversion Efficiency for COCRYSTAL PHARMA NEW O.N. (2021–2025)
The table below shows the annual cash flow conversion efficiency of COCRYSTAL PHARMA NEW O.N. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see COCRYSTAL PHARMA NEW O.N. (8CC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €6.33 Million ≈ $7.40 Million |
€-8.19 Million ≈ $-9.58 Million |
-1.294x | +25.25% |
| 2024-12-31 | €9.52 Million ≈ $11.13 Million |
€-16.48 Million ≈ $-19.27 Million |
-1.731x | -211.42% |
| 2023-12-31 | €26.38 Million ≈ $30.85 Million |
€-14.67 Million ≈ $-17.15 Million |
-0.556x | -2.61% |
| 2022-12-31 | €39.57 Million ≈ $46.26 Million |
€-21.43 Million ≈ $-25.06 Million |
-0.542x | -230.30% |
| 2021-12-31 | €77.55 Million ≈ $90.66 Million |
€-12.72 Million ≈ $-14.87 Million |
-0.164x | -- |
About COCRYSTAL PHARMA NEW O.N.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more